Meeting
2014 Gastrointestinal Cancers Symposium
Observational study of the first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial.
Authors
Kei Muro
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
Kei Muro , Michio Itabashi , Hiroki Hashida , Toshiki Masuishi , Masanori Kotake , Tadamichi Denda , Yasuo Ohashi , Kenichi Sugihara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
UMIN000007275
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 539)
DOI
10.1200/jco.2014.32.3_suppl.539
Abstract #
539
Poster Bd #
C44
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Fruquintinib plus capecitabine versus capecitabine as first-line maintenance treatment of metastatic colorectal cancer (mCRC): Update results from the randomized, controlled, phase Ib/II study.
First Author: Wenhua Li
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy of capecitabine as a salvage treatment in metastatic colorectal cancer after prior 5-fluorouracil–included chemotherapies.
First Author: Jae Yeon Jang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer.
First Author: Riya Jayesh Patel
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz